Clinical Pharmacokinetics

, Volume 19, Issue 5, pp 390–399 | Cite as

Clinical Pharmacokinetics of Interferons

  • Robert J. Wills
Drug Disposition

Summary

Interferons are a family of proteins shown to be effective in the treatment of viral (condylomata, acuminata) and neoplastic (hairy cell leukaemia and AIDS-related Kaposi’s sarcoma) diseases. To date, the clinical utility of the interferons has been hampered by an incomplete understanding of their mechanism of action. However, there is supporting evidence that the route of administration, i.e. the pharmacokinetic behaviour, is an important treatment variable.

The pharmacokinetics of interferons have been fairly well described. The decline in serum concentrations of interferon is rapid after intravenous administration. The volume of distribution approximates 20 to 60% of bodyweight. Work in animals suggests that the catabolism of interferons falls within the natural handling of proteins. Clearance values vary (4.8 to 48 L/h) across the family of interferons and probably reflect the natural internal digestion and turnover of these proteins. Terminal elimination half-lives range from 4 to 16 hours, 1 to 2 hours and 25 to 35 minutes for α, β and γ, respectively. Intramuscular and subcutaneous administration of interferons α and β results in protracted but fairly good absorption: >80% for interferon-α and 30 to 70% for interferon-γ.

Interferon therapy is associated with adverse events which are usually mild and reversible. Temporal relationships exist between the degree and duration of adverse effects and the route of administration. Attempts to relate inducible biochemical markers, such as 2′,5′-oligoadenylate synthetase activity, to dose or concentration have met with some success although alterations in these markers have not been shown to relate to clinical response. Interferons can reduce hepatic drug metabolism but further work is needed before a true assessment of clinical relevance can be made. Finally, antibodies to the interferons have been detected but the clinical relevance is still unknown.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Armstrong JA. Cytopathic effect inhibition assay for interferon: microculture plate assay. In Pestka (Ed.) Methods in enzymology. Vol. 78, pp. 381–387, Academic Press, New York, 1981Google Scholar
  2. Ashwell G, Morell AG. The role of surface carbohydrates in the hepatic recognition and transport of circulating glycoproteins. In Meister (Ed.) Advances in enzymology, Vol. 41, pp. 98–128, John Wiley & Sons, New York, 1974Google Scholar
  3. Billiau A, de Somer P, Edy VG, de Clercq E, Heremans H. Human fibroblast interferon for clinical trials: pharmacokinetics and tolerability in experimental animals and humans. Antimicrobial Agents and Chemotherapy 16: 56–63, 1979PubMedCrossRefGoogle Scholar
  4. Bino T, Edery H, Gertler A, Rosenberg H. Involvement of the kidney in catabolism of human leukocyte interferon. Journal of General Virology 59: 39–45, 1982aPubMedCrossRefGoogle Scholar
  5. Bino T, Madar Z, Gertler A, Rosenberg H. The kidney is the main site of interferon degradation. Journal of Interferon Research 2: 301–308, 1982bPubMedCrossRefGoogle Scholar
  6. Bjerke JR, Linden JK, Degre M, Matre R. Interferon in suction blister fluid from psoriatic lesions. British Journal of Dermatology 108: 295–299, 1983PubMedCrossRefGoogle Scholar
  7. Bocci V. Distribution, catabolism and pharmacokinetics of inerferons. In Finter et al. (Eds) In vivo and clinical fluids. Vol. 4, pp. 47–72, Elsevier, New York. 1985aGoogle Scholar
  8. Bocci V, Di Francesco P, Pacini A, Pessina GP, Rossi GB, et al. Renal metabolism of homologous serum interferon. Antiviral Research 3: 53–58, 1983aPubMedCrossRefGoogle Scholar
  9. Bocci V, Maunsboch AB, Mogensen EK. Autoradiographic demonstration of human 125I-interferon alpha in lysosomes of rabbit proximal tubule cells. Journal of Submicroscopic Cytology 16: 753–757, 1984PubMedGoogle Scholar
  10. Bocci V, Mogensen KE, Muscettola M, Pacini A, Paulesu L, et al. Degradation of human 125I-interferon alpha by isolated perfused rabbit kidney and liver. Journal of Laboratory and Clinical Medicine 101: 857–863, 1983bPubMedGoogle Scholar
  11. Bocci V, Pacini A, Bandinelli L, Pessina GP, Muscettola M, et al. The role of liver in the catabolism of human α- and β-interferon. Journal of General Virology 60: 397–400, 1982aPubMedCrossRefGoogle Scholar
  12. Bocci V, Pacini A, Muscettola M, Paulesu L, Pessina GP. Renal metabolism of rabbit serum interferon. Journal of General Virology 55: 297–304, 1981aPubMedCrossRefGoogle Scholar
  13. Bocci V, Pacini A, Muscettola M, Paulesu L, Pessina GP, et al. Renal filtration, absorption and catabolism of human alpha interferon. Journal of Interferon Research 1: 347–352, 1981bPubMedCrossRefGoogle Scholar
  14. Bocci V, Pacini A, Muscettola M, Pessina GP, Paulesu L, et al. The kidney is the main site of interferon catabolism. Journal of Interferon Research 2: 309–314, 1982bPubMedCrossRefGoogle Scholar
  15. Bocci V, Pacini A, Pessina GP, Paulesu L, Muscettola M, et al. Catabolic sites of human interferon-γ. Journal of General Virology 66: 887–891, 1985bPubMedCrossRefGoogle Scholar
  16. Borden EC, Hawkins MJ, Sielaff KM, Storer BM, Schiesel JD, et al. Clinical and biological effects of recombinant interferon-β administered intravenously daily in phase I trial. Journal of Interferon Research 8: 357–366, 1988PubMedCrossRefGoogle Scholar
  17. Bornemann LD, Spiegel HE, Dziewanowska ZE, Krown SE, Colburn WA. Intravenous and intramuscular pharmacokinetics of recombinant leukocyte A interferon. European Journal of Clinical Pharmacology 28: 469–471, 1985PubMedCrossRefGoogle Scholar
  18. Brown TD, Koeller J, Beougher K, Golando J, Bonnern EM, et al. A phase I clinical trial of recombinant DNA gamma interferon. Journal of Clinical Oncology 5: 790–798, 1987PubMedGoogle Scholar
  19. Budd GT, Bukowski RM, Miketo L, Yen-Lieberman B, Proffitt MR. Phase-I trial of Ultrapure human leukocyte interferon in human malignancy. Cancer Chemotherapy and Pharmacology 12: 39–42, 1984PubMedGoogle Scholar
  20. D’Acquisto R, Markman M, Hakes T, Rubin S, Haskins W, et al. A phase I trial of intraperitoneal recombinant gamma-interferon in advanced ovarian carcinoma. Journal of Clinical Oncology 6: 689–695, 1988PubMedGoogle Scholar
  21. Davies HW, Scott GM, Robinson JA, Higgins PG, Wootton R, et al. Comparative intranasal pharmacokinetics of interferon using two spray systems. Journal of Interferon Research 3: 443–449, 1983PubMedCrossRefGoogle Scholar
  22. Degre M, Dahl H, Vandvik B. Interferon in the serum and cerebrospinal fluid in patients with multiple sclerosis and other neurological disorders. Acta Neurologica Scandinavica 53: 152–160, 1976PubMedCrossRefGoogle Scholar
  23. Degre M, Mellbye OJ, Clarke-Jensen O. Immune interferon in serum and synovial fluid in rheumatoid arthritis and related disorders. Annals of the Rheumatic Diseases 42: 672–676, 1983PubMedCrossRefGoogle Scholar
  24. Dinarello CA, Bernheim HA, Duff GW, Le HV, Nagabhushan TL, et al. Mechanism of fever induced by recombinant human interferon. Journal of Clinical Investigation 74: 906–913, 1984PubMedCrossRefGoogle Scholar
  25. Gallati VH. Interferon: wesentlich vereinfachte, enzym-immunologische Bestimmung mit zwei monoklonalen Antikopern. Journal of Clinical Chemistry and Clinical Biochemistry 20: 907–914, 1982Google Scholar
  26. Goldstein D, Sielaff KM, Storer BE, Brown RR, Datta SP, et al. Human biologic response modification by interferon in the absence of measurable serum concentrations: a comparative trial of subcutaneous and intravenous interferon-β serine. Journal of the National Cancer Institute 81: 1061–1068, 1989PubMedCrossRefGoogle Scholar
  27. Green JR, Klein RJ, Friedman-Kien AE. Intralesional administration of large doses of human leukocyte interferon for the treatment of condylomata acuminata. Journal of Infectious Diseases 150: 612–615, 1984CrossRefGoogle Scholar
  28. Grunberg SM, Kempf RA, Venturi CL, Mitchell MS. Phase I study of recombinant γ-interferon given by four-hour infusion. Cancer Research 47: 1174–1178, 1987PubMedGoogle Scholar
  29. Gutterman JU, Fine S, Quesada J, Horning SJ, Levine JF, et al. Recombinant leukocyte A interferon: pharmacokinetics, single-dose tolerance, and biologic effects in cancer patients. Annals of Internal Medicine 96: 549–556, 1982PubMedGoogle Scholar
  30. Gutterman JU, Rosenblum MG, Rios A, Fritsche HA, Quesada JR. Pharmacokinetic study of partially pure γ-interferon in cancer patients. Cancer Research 44: 4164–4171, 1984PubMedGoogle Scholar
  31. Hawkins M, Horning S, Konard M, Anderson S, Sielaff K. Phase I evaluation of a synthetic mutant of β-interferon. Cancer Research 45: 5914–5920, 1985PubMedGoogle Scholar
  32. Hawkins MJ, Borden EC, Merritt JA, Edwards BS, Ball LA, et al. Comparison of the biologic effects of two recombinant human interferons alpha (rA and rD) in humans. Journal of Clinical Oncology 2: 221–226, 1984PubMedGoogle Scholar
  33. Heremans H, Billiau A. The potential role of Interferons and interferon antagonists in inflammatory disease. Drugs 38: 957–972, 1989PubMedCrossRefGoogle Scholar
  34. Jablecki CK, Poplack D, Howell S, Kingsbury D, Cantell K. High-dose intravenous infusions of interferon. Neurology 33: 141–142, 1983Google Scholar
  35. Jacobs L, Herndon R, Freeman A, Cuetter A, Smith WA, et al. Multicenter double-blind study of effect of intrathecally administered natural human fibroblast interferon on exacerbations of multiple sclerosis. Lancet 2: 1411–1413, 1986PubMedCrossRefGoogle Scholar
  36. Jones GJ, Itri LM. Safety and tolerance of recombinant interferon alfa-2α (Roferon-A) in cancer patients. Cancer 57: 1709–1715, 1986PubMedCrossRefGoogle Scholar
  37. Jonkman JHG, Nicholson KH, Farrow PR, Eckert M, Grasmeijer G, et al. Effects of α-interferon on theophylline pharmacokinetics and metabolism. British Journal of Clinical Pharmacology 27: 795–802, 1989PubMedCrossRefGoogle Scholar
  38. Khan NUD, Pulford KAF, Farquharson MA, Howatson A, Stewart C, et al. The distribution of immunoreactive interferon-alpha in normal human tissues. Immunology 66: 201–206, 1989PubMedGoogle Scholar
  39. Kinnula V, Mattson K, Cantell K. Pharmacokinetics and toxicity of inhaled human interferon-α in patients with lung cancer. Journal of Interferon Research 9: 419–423, 1989PubMedCrossRefGoogle Scholar
  40. Kurzrock R, Quesada JR, Rosenblum MG, Sherwin SA, Gutterman JU. Phase I study of iv administered recombinant gamma interferon in cancer patients. Cancer Treatment Reports 70: 1357–1364, 1986PubMedGoogle Scholar
  41. Kurzrock R, Rosenblum MG, Sherwin SA, Rios A, Talpaz M, et al. Pharmacokinetics, single-dose tolerance, and biological activity of recombinant γ-interferon in cancer patients. Cancer Research 45: 2866–2872, 1985PubMedGoogle Scholar
  42. Liberati AM, Biscottini B, Fizzotti M, Schippa M, de Angelis V, et al. A phase I study of human natural interferon-β in cancer patients. Journal of Interferon Research 9: 339–348, 1989PubMedCrossRefGoogle Scholar
  43. Lotzova E, Savary CA, Quesada JR, Gutterman JU, Hersh EM. Analysis of natural killer cell cytotoxicity of cancer patients treated with recombinant interferon. Journal of the National Cancer Institute 71: 903–910, 1983PubMedGoogle Scholar
  44. Martino S, Singhakowinta A. Serial interferon alpha-2 levels in serum and cerebrospinal fluid. Cancer Treatment Reports 68: 1057–1058, 1984PubMedGoogle Scholar
  45. McManus NH. Microtiter assay for interferon: microspectrophotometric quantitation of cytopathic effect. Applied and Environmental Microbiology 31: 35–38, 1976PubMedGoogle Scholar
  46. McPherson TA, Tan YH. Phase I pharmacotoxicology study of human fibroblast interferon in human cancers. Journal of the National Cancer Institute 65: 75–79, 1980PubMedGoogle Scholar
  47. Merritt JA, Ball LA, Sielaff KM, Meltzer DM, Borden EC. Modulation of 2′.5′.-oligoadenylate synthetase in patients treated with alpha-interferon: effects of dose, schedules, and route of administration. Journal of Interferon Research 6: 189–198, 1986PubMedCrossRefGoogle Scholar
  48. Omata M, Imaziki F, Yokosuka O, Ito Y, Uchiumi K, et al. Recombinant leukocyte A interferon treatment in patients with chronic hepatitis B virus infection. Gastroenterology 88: 870–880, 1985PubMedGoogle Scholar
  49. Overall JC, Spruance SL, Green JH. Viral-induced leukocyte interferon in vesicle fluid from lesions of recurrent herpes labialis. Journal of Infectious Diseases 143: 543–547, 1981PubMedCrossRefGoogle Scholar
  50. Parkinson A, Lasker J, Kramer MJ, Huang M-T, Thomas PE, et al. Effects of three recombinant human leukocyte interferons on drug metabolism in mice. Drug Metabolism and Disposition 10: 579–585, 1982PubMedGoogle Scholar
  51. Phillpotts RJ, Davies HW, Willman J, Tyrell DAJ, Higgins PG. Pharmacokinetics of intranasally applied medication during a cold. Antiviral Research 4: 71–74, 1984PubMedCrossRefGoogle Scholar
  52. Priestman TJ, Johnston M, Whiteman PD. Preliminary observations on the pharmacokinetics of human lymphoblastoid interferon given by intramuscular injection. Clinical Oncology 8: 265–269, 1982PubMedGoogle Scholar
  53. Protzman WP, Minnicozzi M, Jacobs SL, Surprenant DI, Schwartz J, et al. Immunoradiometric assay of a recombinant human alpha-2 interferon (SCH 30500). Journal of Clinical Microbiology 22: 596–599, 1985PubMedGoogle Scholar
  54. Quesada JR, Gutterman JU, Hersh EM. Clinical and immunological study of beta interferon by intramuscular route in patients with metastatic breast cancer. Journal of Interferon Research 2: 593–599, 1982PubMedCrossRefGoogle Scholar
  55. Quesada JR, Gutterman JU. Clinical study of recombinant DNA-produced leukocyte interferon (clone A) in an intermittent schedule in cancer patients. Journal of National Cancer Institute 70: 1041–1046, 1983Google Scholar
  56. Radwanski E, Perenthesis G, Jacobs S, Oden E, Affrime M, et al. Pharmacokinetics of interferon α-2b in healthy volunteers. Journal of Clinical Pharmacology 27: 432–435, 1987PubMedGoogle Scholar
  57. Rashidbaigi A, Pestka S. Interferons: protein structure. In Baron et al. (Eds) The interferon system, pp. 149–168, University of Texas Press, Austin. 1988Google Scholar
  58. Rosenberg H, Madar F, Gertler A, Rubinstein M, Bino T. The fate of 125I-labelled human leukocyte-derived alpha interferon in the rat. Journal of Interferon Research 5: 121–127, 1985PubMedCrossRefGoogle Scholar
  59. Rubinstein S, Famillctti PC, Pestka S. Convenient assay for interferons. Journal of Virology 37: 755–758, 1981PubMedGoogle Scholar
  60. Salonen R. CSF and serum interferon in multiple sclerosis: longitudinal study. Neurology 33: 1604–1606, 1983PubMedCrossRefGoogle Scholar
  61. Samo TC, Greenberg SB, Palmer JM, Couch RB, Harmon MW, et al. Intranasally applied recombinant leukocyte A interferon in normal volunteers: II. Determination of minimal effective and tolerable dose. Journal of Infectious Diseases 150: 181–188, 1984PubMedCrossRefGoogle Scholar
  62. Sarna G, Pertcheck M, Figlin R, Ardalan B. Phase I study of recombinant ser 17 interferon in the treatment of cancer. Cancer Treatment Reports 70: 1365–1372, 1986PubMedGoogle Scholar
  63. Secher DS. Immunoradiometric assay of human leukocyte interferon using monoclonal antibody. Nature 290: 501–503, 1981PubMedCrossRefGoogle Scholar
  64. Secor J, Schenker S. Effect of recombinant α-interferon on in vivo and in vitro markers of drug metabolism in mice. Abstract no. 298, Hepatology 4: 1081, 1984Google Scholar
  65. Shah I, Band J, Samson M, Young J, Robinson R, et al. Pharmacokinetics and tolerance of intravenous and intramuscular recombinant alpha-2 interferon in patients with malignancies. American Journal of Hematology 17: 363–371, 1984PubMedCrossRefGoogle Scholar
  66. Sherwin SA, Knost JA, Fein S, Abrams PG, Foon KA, et al. A multiple-dose phase I trial of recombinant leukocyte A interferon in cancer patients. Journal of the American Medical Association 248: 2461–2466, 1982PubMedCrossRefGoogle Scholar
  67. Smith RA, Kingsbury D, Alksne J, James H, Cantell K. Distribution of interferon in cerebrospinal fluid after systemic, intrathecal, and intraventricular administration. Annals of Neurology 12: 81, 1982Google Scholar
  68. Smith RA, Norris F, Palmer D, Bernhardt L, Wills RJ. Distribution of alpha interferon in serum and cerebrospinal fluid after systemic administration. Clinical Pharmacology and Therapeutics 37: 85–88, 1985PubMedCrossRefGoogle Scholar
  69. Sonnenfeld G, Harned CL, Newerland DE. Effects of interferon on drug metabolism. Texas Reports on Biology and Medicine 41: 363–369, 1981PubMedGoogle Scholar
  70. Spiegel RJ, Intron A (interferon alfa-2b): clinical overview. Cancer Treatment Reviews 12 (Suppl. B): 5–16, 1985PubMedGoogle Scholar
  71. Taylor G, Marafino BJ, Moore JA, Gurley V, Blaschke JF. Interferon reduces hepatic drug metabolism in vivo in mice. Drug Metabolism and disposition 13: 459–463, 1985PubMedGoogle Scholar
  72. Thompson JA, Cox WW, Lindgren CG, Collins C, Neraas KA, et al. Subcutaneous recombinant gamma interferon in cancer patients: toxicity pharmacokinetics and immunomodulatory effects. Cancer Immunology and Immunotherapy 25: 47–53, 1987PubMedGoogle Scholar
  73. Tokazewski-Chen SA, Marafino BJ, Stebbing N. Effects of nephrectomy on the pharmacokinetics of various cloned human interferons in rats. Journal of Pharmacology and Experimental Therapeutics 227: 9–15, 1983PubMedGoogle Scholar
  74. Turner RB, Durcan FJ, Albrecht JK, Crandall AS. Safety and tolerance of ocular administration of recombinant alpha interferons. Antimicrobial Agents and Chemotherapy 33: 396–397, 1989PubMedCrossRefGoogle Scholar
  75. Vadhan-Raj S, Nathan CF, Sherwin SA, Oettgen HF, Krown SE. Phase I trial of recombinant interferon gamma by l-hr iv infusion. Cancer Treatment Reports 70: 609–614, 1986PubMedGoogle Scholar
  76. Van der Burg M, Edelstein M, Gerlis L, Liang CM, Hirschi MN, et al. Recombinant interferon-γ (Immuneron) results of a phase I trial in patients with cancer. Journal of Biological Response Modifiers 4: 264–272, 1985PubMedGoogle Scholar
  77. Vilcek J, Gray PW, Rinderknecht E. Interferon-gamma: a lymphokine for all seasons. In Peck (Ed.) Lymphokines, Vol. 12. pp. 1–32, Academic, Orlando, 1985Google Scholar
  78. Von Wussow P, Borden EC. Antibodies to interferons in patients: defining their significance. Journal of Interferon Research 9 (Suppl. 1): 51–572, 1989Google Scholar
  79. Walker JR, Nagington J, Scott GM, Seeker DS. Immunoradiometric assay of serum interferon using a monoclonal antibody. Journal of General Virology 62: 181–185, 1982PubMedCrossRefGoogle Scholar
  80. Wells RJ, Weck PK, Boehner RL, Krivit W, Raney RB, et al. Interferon in children with recurrent acute lymphocytic leukemia: a phase I study of pharmacokinetics and tolerance. Journal of Interferon Research 8: 309–318, 1988PubMedCrossRefGoogle Scholar
  81. Williams SJ, Farrell GC. Inhibition of antipyrene metabolism by interferon. British Journal of Clinical Pharmacology 22: 610–612, 1986PubMedCrossRefGoogle Scholar
  82. Williams SJ, Baìrd-Lambert JA, Farrell GC. Inhibition of theophylline metabolism by interferon. Lancet: 939-941, 1987Google Scholar
  83. Wills RJ, Dennis S, Spiegel HE, Gibson DM, Nadler PI. Interferon kinetics and adverse reactions after intravenous, intramuscular and subcutaneous injection. Clinical Pharmacology and Therapeutics 35: 722–727, 1984PubMedCrossRefGoogle Scholar
  84. Wills RJ, Spiegel HE. Continuous intravenous infusion pharmacokinetics of interferon to patients with leukemia. Journal of Clínícal Pharmacology 25: 616–619, 1985PubMedGoogle Scholar
  85. Witter F, Barouki F, Griffin D, Nadler P, Woods A, et al. Biologic response (antiviral) to recombinant human interferons alpha 2a as a function of dose and route of administration in healthy volunteers. Clinical Pharmacology and Therapeutics 42: 567–575, 1987PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 1990

Authors and Affiliations

  • Robert J. Wills
    • 1
  1. 1.R.W. Johnson Pharmaceutical Research InstituteRaritanUSA

Personalised recommendations